Clinical trials: Mosquito-Borne Diseases
Malaria, Asymptomatic Malaria
Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission
Primaquine (PQ) is currently the only available drug that can clear the mature transmission stages of P. falciparum parasites. PQ was previously shown to clear gametocytes that persist after artemisinin-combination therapy.
- Conditions
- Malaria, Asymptomatic Malaria, Plasmodium Falciparum
- Trial name
- DAPPI (NCT02259426)
- Testing
- Dihydroartemisinin-piperaquine combination (Artekin), Primaquine
- Where
- Kenya
- Volunteers
- 120 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Vivax Infection
Ethiopia Antimalarial in Vivo Efficacy Study 2012
The investigators hypothesize that the addition of primaquine (PQ) to both artemether-lumefantrine (AL) and chloroquine (CQ) for the treatment of Plasmodium vivax infection will result in decreased chance of relapse by about 60%.
- Trial name
- NCT01680406
- Testing
- Artemether-lumefantrine combination, Primaquine, Chloroquine
- Where
- 2 sites in Ethiopia
- Volunteers
- 398 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Placental Malaria
Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria
This study seeks to determine whether screening pregnant women for malaria with malaria rapid diagnostic tests (RDTs) may detect placental infection and predict risk of poor birth outcomes due to malaria in areas of varied…
- Conditions
- Malaria, Placental Malaria, Malaria in Pregnancy
- Trial name
- NCT01555255
- Where
- 2 sites in Burkina Faso, Uganda
- Volunteers
- 1,205 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Dengue Fever
The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia
Dengue infection has been identified as the fastest spreading mosquito-borne viral disease by World Health Organization (WHO), which affects more than 2.5 billion people living in the subtropical and tropical regions.
- Trial name
- NCT02510638
- Where
- Malaysia
- Volunteers
- 322 people
- Sponsor
- Clinical Research Centre, Malaysia
Severe Malaria
Malaria Treatment With Injectable ArteSunate
The MATIAS study aims to demonstrate through limited scope implementation studies how injectable artesunate may be progressively rolled out nationwide in the Democratic Republic of the Congo as the preferred treatment for severe…
- Trial name
- MATIAS (NCT01828333)
- Testing
- No intervention
- Where
- 9 sites in Democratic Republic of the Congo
- Volunteers
- 350 people
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria (Plasmodium Falciparum), Malaria Falciparum
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda.
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Falciparum, Malaria Infection, Malaria Prophylaxis
- Trial name
- NCT07548021
- Testing
- MMV371
- Where
- Rwanda
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Zika Virus
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms.
- Trial name
- NCT06805487
- Testing
- TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali
This study, sponsored by NIAID and the University of Bamako, Mali, will identify genetic and other factors that may protect against severe malaria in some children.
- Trial name
- NCT00669084
- Where
- Mali
- Volunteers
- 1,718 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Zika Virus Infection
ZIKA Vaccine in Naive Subjects
This study is a study to evaluate the safety of ZPIV. Three dose levels may be evaluated. The entire duration of each subject's participation is approximately 14 months including recruitment and collection of data on the safety…
- Trial name
- NCT02952833
- Testing
- Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Zika, Zika Virus Infection
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
This phase 1 clinical trial consists of an initial open-label sentinel run-in (n=25) and a randomized, double-blind, dose-finding (n=125) investigating three antigen dose levels (low, medium and high) of VLA1601 and bedside…
- Trial name
- NCT06334393
- Testing
- VLA1601, CpG 1018®, 3M-052-AF
- Where
- 4 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Malaria
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
This randomized, double-blind, placebo-controlled, Phase 1 trial will enroll up to 22 malaria-naïve, adult participants to test safety, tolerability, immunogenicity, and efficacy of the genetically attenuated Plasmodium…
- Trial name
- NCT06735209
- Testing
- PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Adult, Healthy Adolescents
Evaluation of IXCHIQ® Vaccine Immunogenicity
The goal of this clinical trial is to evaluate the quality and duration of the immune response against chikungunya virus elicited by the IXCHIQ® vaccine in healthy adults and adolescents.
- Trial name
- IMUNO-CHIQ (NCT07846293)
- Testing
- IXCHIQ vaccine
- Where
- Brazil
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mauro Martins Teixeira
Malaria, Falciparum
Chloroquine and Amodiaquine for Treatment of Malaria in Children
This study will evaluate the efficacy of the treatment recommended by the National Malaria Programme in Guinea-Bissau as compared to a higher dose of chloroquine and to another anti-malarial drug, amodiaquine.
- Trial name
- NCT00137514
- Testing
- chloroquine, amodiaquine
- Where
- Guinea-Bissau
- Volunteers
- 720 people
- Sponsor
- Bandim Health Project
Malaria
A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. ChAd Pfs-IMX313 will either be administered alone or with MVA Pfs25-IMX313 in a prime-boost regime.
- Trial name
- NCT02532049
- Testing
- ChAd63 Pfs25-IMX313, MVA Pfs25-IMX313
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pneumonia, Diarrhea
Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children
Children hospitalized with severe illness in sub-Saharan Africa are at high risk of morbidity and mortality following discharge from hospital.
- Conditions
- Pneumonia, Diarrhea, Malaria, Co-infection
- Trial name
- Toto Bora (NCT02414399)
- Testing
- Azithromycin
- Where
- Kenya
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Washington
Malaria,Falciparum, Feasibility
Malaria Vaccine Pilot Evaluation
The RTS,S/AS01 malaria vaccine is being introduced sub-nationally in phased pilot introductions through the EPI programmes in Malawi Ghana and Kenya.
- Conditions
- Malaria,Falciparum, Feasibility, Safety, Mortality
- Trial name
- MVPE (NCT03806465)
- Testing
- Feasibility survey, Sentinel hospital surveillance, Community mortality surveillance
- Where
- 3 sites in Ghana, Kenya and 1 more
- Volunteers
- 30,124 people, healthy volunteers welcome
- Sponsor
- Rafiq OKINE
Dengue
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
AIMS \& OBJECTIVES To evaluate the effectiveness of administering of Carica folia mother tincture to healthy individual's Platelet count.
- Trial name
- CF2013 (NCT02016027)
- Testing
- Carica folia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fr Muller Homoeopathic Medical College
Malaria Fever
A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
The goal of the study is to test the efficacy using a homologous CHMI of this vaccine candidate early in the development path in a population living in malaria-endemic areas.
- Trial name
- CHMI-SUM-101 (NCT07124156)
- Testing
- SUM-101, CHMI, Verorab®
- Sponsor
- European Vaccine Initiative
Malaria
Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan
Dihydroartemisinin- Piperaquine is not inferior to artemether-lumefantrine
- Trial name
- NCT01075945
- Testing
- Dihydroartemisinin- piperaquine, artemether- lumefantrine
- Where
- Sudan
- Volunteers
- 140 people
- Sponsor
- University of Khartoum
Malaria, Pregnant
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
Randomized controlled single blind prospective comparative study
- Conditions
- Malaria, Pregnant, HIV
- Trial name
- NCT02527005
- Testing
- Sulphadoxine-pyrimethamine, Azithromycin
- Where
- Nigeria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Ibadan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.